Dr. Yanagiya from our business development will deliver a poster presentation at the 19^th Vaccine Congress, which will be held from September 7^th (Sun) to 10^th (Wed), 2025, at the Kyoto International Conference Center. We cordially invite all conference participants to the poster.

【Event details】
Official website: https://www.elsevier.com/events/conferences/all/vaccine-congress
Date:                  September 7^th (Sun) -10^th (Wed), 2025
Venue:               Kyoto International Conference Center
Access:              https://www.icckyoto.or.jp/

【Poster presentation】
Title:                  Strategies to develop efficient and safe mRNA-based therapeutics
Time:                 From 5:30 pm to 7:00 pm in the poster session 1 on September 7^th (Sun)
Presenter:          Dr. Akiko Yanagiya

【Abstract】
mRNA-based therapeutics contribute to the development of vaccines, immunotherapies, and protein replacement therapies through rapid design, efficient protein expression, and scalable production. ARCALIS, Inc., a CDMO, offers seamless services from mRNA development to large-scale manufacturing and, with our sister company, Axcelead Drug Discovery Partners, Inc., supports preclinical testing for IND applications. ARCALIS capability was demonstrated by commercial production of the self-amplifying mRNA (saRNA) COVID-19 vaccine, KOSTAIVE®.

We present four proprietary technologies: (1) a saRNA platform showing sustained, efficient protein expression in mice; (2) HARNA^TM, a machine-learning–based codon optimization tool developed with Hitachi, which prolonged erythropoietin (EPO) expression in vivo; (3) a T7 RNA polymerase minimizing dsRNA impurities; and (4) a nuclease P1–based assay for capping efficiency. Together, these innovations advance the development of safer and more effective mRNA therapeutics.